There is described a pharmaceutical combination comprising oxybutynin or apharmaceutically acceptable additionsalt thereof, in a transdermal therapeutic system, and an acetylcholinesteraseinhibitor, useful for safely treating hypocholinergic disordersof the central nervous system such as Alzheimer type dementia. In thiscombination, the acetylcholinesterase inhibitor(AChEI) is present at a dose that is higher than the maximal recommended dose,per unit form. In particular, the transdermal therapeuticsystem comprising oxybutynin is in combination with rivastigmine in atransdermal formulation or oral form.
